NVS Financials

Income Statement
MetricQ2 2016Q1 2016Q4 2015Q3 2015Q2 2015
Revenue
12.7B
+7.4%
11.8B
-7.8%
12.8B
+2.6%
12.5B
-3.2%
12.9B
Cost of Revenue
4.5B
+5.7%
4.2B
-7.4%
4.5B
+3.7%
4.4B
-2.2%
4.5B
Gross Profit
8.2B
+8.3%
7.6B
-8.0%
8.3B
+2.0%
8.1B
-3.7%
8.4B
Operating Expenses
6.4B
+19.2%
5.3B
-15.9%
6.4B
+12.5%
5.7B
-12.8%
6.5B
R&D
2.2B
+7.3%
2.0B
-17.4%
2.5B
+12.9%
2.2B
-0.7%
2.2B
SG&A
3.6B
+10.4%
3.3B
-14.9%
3.9B
+12.2%
3.5B
-4.3%
3.6B
Operating Income
1.9B
-17.7%
2.3B
+18.7%
1.9B
-22.3%
2.4B
+27.0%
1.9B
EBITDA
3.3B
-8.3%
3.6B
+90.8%
1.9B
-50.0%
3.8B
+10.7%
3.4B
Net Income
1.8B
-10.2%
2.0B
+90.4%
1.1B
-44.3%
1.9B
+3.1%
1.8B
EPS (Basic)
$0.76
-10.6%
$0.85
+84.8%
$0.46
-41.8%
$0.79
+3.9%
$0.76
EPS (Diluted)
$0.75
-10.7%
$0.84
+86.7%
$0.45
-41.6%
$0.77
+2.7%
$0.75
Shares (Diluted)
2.4B
+0.1%
2.4B
-1.7%
2.4B
+0.1%
2.4B
-0.5%
2.5B
Novartis (NVS) โ€” Financials